Publication

Human Papillomavirus (HPV) vaccine effectiveness and potential herd immunity for reducing oncogenic oropharyngeal HPV-16 prevalence in the United Kingdom: a cross-sectional study

Authored by:

Mehanna H, Bryant TS, Babrah J et al.

Full Citation:

Mehanna H, Bryant TS, Babrah J et al. 2018. Human Papillomavirus (HPV) vaccine effectiveness and potential herd immunity for reducing oncogenic oropharyngeal HPV-16 prevalence in the United Kingdom: a cross-sectional study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciy1081.

View Publication

Additional key concepts from this publication:

Immunization can help protect unimmunized children, adults and the elderly through herd effects.

Key Evidence: HPV vaccine given to young women may also protect similarly-aged men against oropharyngeal cancers, which have been rising in incidence in the U.S. and Western Europe. In a small study in the UK, rates of oral HPV infections caused by HPV-16 were similar for males 12-24 years of age and vaccinated females (0% vs. 0.5%). This was considerably lower than the rates for unvaccinated females (5.6%) and men ≥25 years old (7.1%).

From the VoICE Editors: HPV-16 is the main HPV type linked to oropharyngeal cancers